AstraZeneca invests $2B in Summit, expands oncology collaboration

AstraZeneca is injecting US$2 billion into Summit Therapeutics and deepening their oncology partnership, signaling a major strategic bet on the biotech's pipeline. The deal boosts Summit's financial position and validates its drug development prospects, while expanding AstraZeneca's oncology portfolio. Market impact is likely positive for Summit shares and modestly positive for AstraZeneca's long-term growth narrative.